Richard Christopher

This profile gathers the share dealings of Richard Christopher across 4 companies, led by Dusa Pharmaceuticals Inc, Icad Inc and Lexaria Bioscience Corp. In total, 46 filings cover trades dated from 9 May 2008 to 29 July 2025.

In open-market terms, that means 4 purchases worth €124k on one side and 13 sales worth €178k on the other. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 24 share grants and 3 option exercises. Since January 2025: 1 purchase and no sales on the market.

In size, the median ticket on the buying side is €49k. Clusters matter here: 1 out of 3 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 33% of cases, with a median move of -53.3%. This is a record of the past, not a forecast.

The latest filing, published on 30 July 2025, reports an open-market purchase of €12k in Lexaria Bioscience Corp. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.